Congenital Adrenal Hyperplasia Companies

Neurocrine Biosciences Phase 3 results for NBT274, a potential first-line oral glucocorticoid replacement therapy for patients with classic CAH, were recently presented at the 2023 Endocrine Society's Annual Meeting. Results showed NBT274 effectively controlled hyperandrogenism with fewer side effects compared to standard treatment.

Millendo Therapeutics Announced positive preliminary data from their Phase 1b/2a clinical trial of MTL-1193, a novel once-daily oral mineralocorticoid receptor agonist for CAH. The study demonstrated good safety and tolerability, paving the way for further development.

Spruce Biosciences Achieved positive interim results from its Phase 2 trial of SPRUCE-718, a gene therapy candidate for CAH. The trial showed SPRUCE-718 could potentially restore cortisol production and reduce dependence on glucocorticoid replacement therapy.

List of Congenital Adrenal Hyperplasia Key Companies in the Market

• Neurocrine Biosciences, Inc. (U.S.)


• Fusion I.P. plc (U.K.)


• Novartis AG (Switerzland)


• Mitsubishi Chemical Holdings Corporation (Japan)


• Johnson & Johnson (U.S.)


• GlaxoSmithKline Plc (U.S.)


• Cadila Healthcare (India)


• Sanofi (France)


• Macleods Pharmaceuticals (India)


• GlaxoSmithKline Plc. (U.K.)


• Allergan (Ireland), Abbott (U.S.)


• Hoffmann-La Roche Ltd. (Switzerland)


• Eli Lilly and Company (U.S.)


• AstraZeneca Plc. (U.K.)


• Merck & Co., Inc. (U.S.)